EMG Guided Botulinum Toxin Injection for Adductor Spasmodic Dysphonia

CSurgeries ◽  
2016 ◽  
Author(s):  
Christian Lava ◽  
Hagit Shoffel-Havakuk ◽  
Michael M Johns III
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Injection ◽  
Spasmodic Dysphonia ◽  
Adductor Spasmodic Dysphonia

Adductor spasmodic dysphonia: case reports withacoustic analysis following botulinum toxin injection and acupuncture

1997 ◽  
Vol 11 (2) ◽  
pp. 232-237 ◽  
Author(s):  
Lise Crevier-Buchman ◽  
Ollivier Laccourreye ◽  
Jean-François Papon ◽  
Dominique Nurit ◽  
Daniel Brasnu
Keyword(s):  
Botulinum Toxin ◽  
Case Reports ◽  
Botulinum Toxin Injection ◽  
Spasmodic Dysphonia ◽  
Adductor Spasmodic Dysphonia

scholarly journals Treatment Efficacy of Electromyography versus Fiberscopy-Guided Botulinum Toxin Injection in Adductor Spasmodic Dysphonia Patients: A Prospective Comparative Study

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
Jae Wook Kim ◽  
Jae Hong Park ◽  
Ki Nam Park ◽  
Seung Won Lee
Keyword(s):  
Botulinum Toxin ◽  
Treatment Efficacy ◽  
Botulinum Toxin Injection ◽  
Spasmodic Dysphonia ◽  
Total Dosage ◽  
Adductor Spasmodic Dysphonia ◽  
Prospective Comparative Study ◽  
The Mean ◽  
Botulinum Toxin Injections ◽  
The Voice

Introduction. This study prospectively evaluates and compares the treatment efficacy of botulinum toxin injection under electromyography guidance (EMG group) and percutaneous botulinum toxin injection under flexible fiberscopic guidance (fiberscopy group).Methods. Thirty patients with adductor spasmodic dysphonia (ADSD), who had never received treatment, were randomly allocated into EMG- or fiberscopy-guided botulinum toxin injections between March 2008 and February 2010. We assessed acoustic and aerodynamic voice parameters, and the voice handicap index (VHI) before injection and at 1, 3, and 6 months after injection.Results. The mean total dosage of botulinum toxin was similar for both groups: 1.7 ± 0.5 U for the EMG group and 1.8 ± 0.4 U for the fiberscopy group (P>0.05). There were no significant differences in outcomes between the two groups in either the duration of effectiveness or complications such as breathy voice and aspiration.Conclusion. Botulinum toxin injection under fiberscopic guidance is a viable alternative to EMG-guided botulinum toxin injection for the treatment of adductor spasmodic dysphonia when EMG equipment is unavailable.

Point-Touch Technique of Botulinum Toxin Injection for the Treatment of Spasmodic Dysphonia

1992 ◽  
Vol 101 (11) ◽  
pp. 883-887 ◽  
Author(s):  
David C. Green ◽  
Paul H. Ward ◽  
Gerald S. Berke ◽  
Bruce R. Gerratt
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Injection ◽  
Current Method ◽  
Spasmodic Dysphonia ◽  
Needle Placement ◽  
Careful Evaluation ◽  
Anatomic Landmarks ◽  
Adductor Spasmodic Dysphonia ◽  
Botox Injection ◽  
Thyroarytenoid Muscle

Intralaryngeal injections of botulinum toxin (Botox), under electromyographic guidance, have emerged as an effective treatment for adductor spasmodic dysphonia. To remain effective, these injections must be repeated every 3 to 9 months as the symptoms recur. One drawback to the current method is the need for electromyographic confirmation of needle placement into the thyroarytenoid muscle. This report describes an anatomic approach to Botox injection that requires only flexible nasopharyngeal endoscopy and careful evaluation of the anatomic landmarks. This technique has been used successfully on 13 patients, and objective pretreatment and posttreatment measures are reported.

The Effects of Botulinum Toxin Injection Treatment Administered to Patients with Adductor Spasmodic Dysphonia

2017 ◽  
Vol 58 (3) ◽  
pp. 237-245
Author(s):  
Fukie Omori ◽  
Miyoko Ishige ◽  
Takeo Kobayashi ◽  
Eiko Hirota ◽  
Masaaki Suzuki
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Injection ◽  
Spasmodic Dysphonia ◽  
Injection Treatment ◽  
Adductor Spasmodic Dysphonia

The point-touch technique for botulinum toxin injection in adductor spasmodic dysphonia: quality of life assessment

2011 ◽  
Vol 125 (7) ◽  
pp. 714-718 ◽  
Author(s):  
S Morzaria ◽  
E J Damrose
Keyword(s):  
Quality Of Life ◽  
Botulinum Toxin ◽  
Assessment Tool ◽  
Botulinum Toxin Injection ◽  
Spasmodic Dysphonia ◽  
Life Questionnaire ◽  
Adductor Spasmodic Dysphonia ◽  
Related Quality ◽  
Pre Treatment

AbstractBackground:Botulinum toxin injection under electromyographic guidance is the ‘gold standard’ for adductor spasmodic dysphonia treatment. The point-touch technique, an alternative injection method which relies on anatomical landmarks, is cheaper, quicker and more accessible, but has not yet gained widespread acceptance due to concerns about patient satisfaction.Objective:To assess swallowing and voice-related quality of life following point-touch botulinum toxin injection in adductor spasmodic dysphonia patients.Setting:Stanford University Voice and Swallowing Center.Design:Prospective case series (evidence level four).Methods:Consecutive adductor spasmodic dysphonia patients with a stable botulinum toxin dose–response relationship were recruited prospectively. The Eating Assessment Tool and Voice-Related Quality of Life questionnaires were completed pre-treatment and at 10 and 30 per cent completion of the injection cycle, respectively.Results:Thirty-seven patients completed follow up. The mean total botulinum toxin dose was 0.88 units. Pre-treatment Voice-Related Quality of Life questionnaire results reflected the burden of disease. Post-treatment Eating Assessment Tool and Voice-Related Quality of Life questionnaire results were collected at 2.53 and 7.84 weeks, respectively; the former showed an increase in dysphagia, albeit statistically insignificant, while the latter showed significantly improved scores (both domain and total).Conclusion:The point-touch technique is a viable alternative for botulinum toxin injection in the treatment of adductor spasmodic dysphonia.

Effects of Botulinum Toxin on Pathophysiology in Spasmodic Dysphonia

2000 ◽  
Vol 109 (2) ◽  
pp. 194-203 ◽  
Author(s):  
Steven Bielamowicz ◽  
Christy L. Ludlow
Keyword(s):  
Botulinum Toxin ◽  
Muscle Activity ◽  
Muscle Activation ◽  
Botulinum Toxin Injection ◽  
Symptom Relief ◽  
Spasmodic Dysphonia ◽  
Laryngeal Muscle ◽  
Adductor Spasmodic Dysphonia ◽  
Before And After ◽  
Thyroarytenoid Muscle

To determine the mechanism of symptom relief with treatment by botulinum toxin injection in persons with adductor spasmodic dysphonia (ADSD), we evaluated the effects of unilateral thyroarytenoid muscle injections on both injected and noninjected muscles in 10 subjects with ADSD, using electromyography on both sides of the larynx before and after treatment. The subjects' speech symptoms were reduced (p = .005) 2 weeks following injection, when the electromyographic study occurred. Muscle activation levels and the numbers of spasmodic muscle bursts decreased significantly (p ≤ .03) postinjection in both the injected and noninjected muscles. The reductions in laryngeal muscle bursts correlated with symptom reduction (r ≥ .7) in all muscles. Reductions in laryngeal muscle bursts did not relate to either absolute or normalized levels of muscle activity before or after botulinum toxin injection. The results suggest that changes in the central pathophysiology are responsible for changes in speech symptoms following treatment.

Sign in / Sign up

Export Citation Format

Share Document